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Previously, we demonstrated that a fusion protein (Gal-FMDV) consisting of h-galactosidase and an immunogenic peptide, amino acids
(141–160)–(21–40)–(141–160), of foot-and-mouth disease virus (FMDV) VP1 protein induced protective immune responses in guinea pigs
and swine. We now designed a new potential recombinant protein vaccine against FMDV in swine. The immunogenic peptide, amino acids
(141–160)–(21–40)–(141–160) from the VP1 protein of serotype O FMDV, was fused to the carboxy terminus of a swine immunoglobulin G
single heavy chain constant region and expressed in Escherichia coli. The expressed fusion protein (IgG-FMDV) was purified and emulsified
with oil adjuvant. Vaccination twice at an interval of 3 weeks with the emulsified IgG-FMDV fusion protein induced an FMDV-specific
spleen proliferative T-cell response in guinea pigs and elicited high levels of neutralizing antibody in guinea pigs and swine. All of the
immunized animals were efficiently protected against FMDV challenge. There was no significant difference between IgG-FMDV and Gal-
FMDV in eliciting immunity after vaccination twice in swine. However, when evaluating the efficacy of a single inoculation of the fusion
proteins, we found that IgG-FMDV could elicit a protective immune response in swine, while Gal-FMDVonly elicited a weak neutralizing
activity and could not protect the swine against FMDV challenge. Our results suggest that the IgG-FMDV fusion protein is a promising
vaccine candidate for FMD in swine.
D 2004 Elsevier Inc. All rights reserved.
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Foot-and-mouth disease (FMD) is a highly contagious
and economically devastating viral disease of cloven-hoofed
livestock. The causative agents of FMD are small icosahe-
dral viruses of the Aphthovirus group within the Picornavir-0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
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sota, Minneapolis, MN 55455, USA.idae family (Belsham, 1993; Pereira, 1981). FMD virus
(FMDV) exhibits a high potential for genetic and antigenic
variation, which has led to the classification of seven
serotypes: A, O, C, Asia I, SAT1, SAT2, and SAT3. The
infectious particle is composed of 60 copies each of four
structural proteins (VP1, VP2, VP3, and VP4) that enclose a
single-stranded, positive sense RNA genome (Barteling and
Vreeswijk, 1992; Baxt et al., 1984). VP1 carries important
immunogenic sites recognized by host immune cells,
including amino acids (aa) 141–160, a major B cell site,
and aa21–40, a T-cell site (Baxt et al., 1984; Collen et al.,
1991; Strohmaier et al., 1982).04) 274–281
Fig. 1. Expression plasmid construction. DNA fragment encoding the swine
IgG heavy chain constant region gene and an immunogenic peptide of
(141–160)–(21–40)–(141–160) from VP1 was cloned into the pTricHis
vector. Ptrc = trc promoter; Ap
r = ampicillin; 141–160 = amino acids 141–
160 of FMDV VP1 protein; 21–40 = amino acids 21–40 of FMDV VP1
protein.
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FMD, especially in endemic areas. Toward this aim,
various vaccine-development approaches were undertaken.
These include use of chemically inactivated viruses
emulsified with adjuvant (Barteling and Vreeswijk, 1992;
Sa˜iz et al., 2002), modified live-virus (Mason et al., 1997;
McKenna et al., 1995), synthetic peptides (Bittle et al.,
1982; Dimarchi et al., 1986; Wang et al., 2002),
recombinant proteins (Broekhuijsen et al., 1987; Syred et
al., 1987), recombinant virus (Berinstein et al., 2000;
Chinsangaram et al., 2003; Mayr et al., 1999; Wu et al.,
2003), and DNA vaccines (Cedillo-Barron et al., 2003;
Chinsangaram et al., 1998). Among these strategies, the
development of safe and effective recombinant protein
FMD vaccines that contain a large foreign protein carrier
and FMD immunogenic epitopes constitutes an interesting
goal (Zheng et al., 1994).
We have previously developed a recombinant protein
FMD vaccine that contains h-galactosidase and a
peptide of immunogenic sites consisting of two copies
of aa141–160 and one copy of aa21–40 from VP1
(Huang et al., 1999). This fusion protein can elicit high
levels of neutralizing antibody and an FMDV-specific
proliferative T-cell response in guinea pigs and swine,
as well as efficiently protect the immunized animals
against viral challenge. However, repeated immunization
with this recombinant protein may result in an
undesirable immune response due to non-specific immu-
nogenicity generated by the h-galactosidase carrier
protein.
To avoid the side effects of excess immunogenicity
caused by h-galactosidase, we have designed a new
vaccine candidate by replacing h-galactosidase with the
swine IgG single heavy chain constant region. The
reasons for choosing swine IgG heavy chain constant
region as the epitope carrier are: (1) Swine IgG is a self-
molecule; (2) immunoglobulins have been suggested as
one of the most suitable candidates to replace the
microbial protein used as a carrier among self-molecules
(Bona et al., 1994). (3) We once chose swine IgG heavy
chain as the carrier for FMDV epitopes by replacing the
complementary-determining region 3 (CDR3) with FMDV
antigenic peptide, but the created chimeric protein can
just elicit a weak immune response in guinea pigs and
swine and cannot protect efficiently the immunized
animals against viral infection (Zhao et al., 2000). In
the current study, the fusion protein IgG-FMDV was
created by fusing an immunogenic peptide consisting of
two copies of aa141–160 and one copy of aa21–40 of
serotype O FMDV VP1 to the carboxy terminus of the
swine single heavy chain constant region. The IgG-
FMDV was expressed in Escherichia coli and was then
used to immunize guinea pigs and swine. T-cell prolifer-
ative responses, neutralizing activities and protections
against viral infection elicited by IgG-FMDV were
investigated in the immunized animals.Results
Expression, purification and Western blot assay of
IgG-FMDV fusion protein
The swine IgG single heavy chain constant region was
amplified by PCR. An immunogenic peptide consisting of
two copies of aa141–160 and one copy of aa21–40 from
VP1 protein was fused to the carboxy terminus of the swine
IgG single heavy chain constant region to create a chimeric
protein (IgG-FMDV) (Fig. 1). The IgG-FMDV fusion
protein was expressed in E. coli after induction with IPTG
(Fig. 2A, lane 2). To confirm the presence of the FMDV
insert, the cultures were detected by Western blot analysis
using an anti-FMDV antibody. As shown in Fig. 2A, the
IgG-FMDV fusion protein could be recognized by anti-
FMDV antibody (Fig. 2A, lane 6), whereas no bands were
found in the cell extracts without IPTG induction, with the
vector without insert, or the extracts without the construct
(Fig. 2A, lanes 7–9). Western blot analysis was also
performed to confirm the absence of reactivity with
preimmune sera of swine used for viral challenge assays.
As expected, no bands were found (Fig. 2A, lanes 10–13).
The expressed IgG-FMDV protein, which forms inclu-
sion body, was partially purified and SDS-PAGE showed
that the target protein consisted 90% of the total proteins
(Fig. 2B, lane 3).
T-cell proliferative response in guinea pig
Two groups of guinea pigs each were immunized with
100 Ag of purified IgG-FMDVor Gal-FMDV fusion protein
Fig. 2. Expression and Western blot analysis of the IgG-FMDV fusion protein. (A) Cells were collected at 6 h after IPTG induction. The cell extracts were
fractionated in SDS-PAGE and then stained with Coomassie brilliant blue (Lanes 1–5). Lane 1, protein marker. Lane 2, IgG-FMDV sample with IPTG
induction. Lane 3, IgG-FMDV sample without IPTG induction. Lane 4, the vector without insert with IPTG induction. Lane 5, sample without the constructs
with IPTG induction. Lanes 6–9: cell extracts corresponding to lanes 2–5 were transferred onto a nitrocellulose membrane for blotting assay with anti-FMDV
antibody. Lanes 10–13: cell extracts corresponding to lanes 2–5 were transferred onto a nitrocellulose membrane for blotting assay with swine preimmune sera.
(B) IgG-FMDV sample collected at 6 h after IPTG induction was sonicated. The inclusion body pellet before purification and after purification was fractionated
in SDS-PAGE and then stained with Coomassie brilliant blue (Lanes 1–3). Lane 1, protein marker. Lane 2, sample before purification. Lane 3, sample after
purification. Lane 4: IgG-FMDV was transferred onto a nitrocellulose membrane for blotting assay with an anti-FMDV antibody.
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received PBS or IgG heavy chain constant region without
FMDV epitopes. Spleen T-cells from all test groups of
guinea pigs were isolated and exposed to five 2-fold serial
dilutions of pure FMDVantigen. The proliferative responses
were expressed as the stimulation index (SI). In Fig. 3, it can
be seen that positive lymphoproliferations (SIN2) against
both IgG-FMDV and Gal-FMDV fusion proteins were
detected when T-cells were stimulated with each of the five
serial dilutions of pure FMDV antigen. The peak ofFig. 3. FMDV-specific proliferative T-cell response in guinea pigs. Spleen
T-cell culture and proliferation assays were performed as described in
Materials and methods. Each SI value represents a mean value from five
guinea pigs. SI z 2 is considered positive.proliferation was observed at an antigen dilution of 1:10.
There is no significant difference between two fusion
proteins in eliciting T-cell proliferation response. As the
antigen used to stimulate cells was purified FMDV antigen,
the T-cell responses were considered FMDV-specific.
Spleen T-cells obtained from the control animals did not
show any significant level of T-cell proliferation response
(SI b 1.5).
Levels of neutralizing antibody response and viral challenge
assay in guinea pigs
Neutralizing antibody response to FMDV is considered
to be the basis of protective immunity (Aggarwal and
Barnett, 2002; Doel, 1999). Phagocytosis of virus–antibody
complexes, following viral opsonization, may mediate viral
clearance in vivo (McCullough et al., 1988). The IgG-
FMDV fusion protein contains two copies of the aa141–160
peptide from VP1 protein. This site has been identified as
the continuous viral epitope recognized by host B-cells to
produce neutralizing antibody (Baxt et al., 1984; Collen et
al., 1991; Strohmaier et al., 1982). To examine the levels of
neutralizing antibody in the immunized guinea pigs, blood
serum was collected before immunization and at weeks 3
and 7 after secondary administration. The neutralizing
antibody levels were examined using a suckling mouse
protection test. In our previous experience, successful
Table 2
Neutralizing antibody titers and viral challenge assays in swine receiving
two inoculations at an interval of 3 weeks
Groups Animal no. Neutralizing titers No. protected/
No. challengedWeek 0 Week 6
IgG-FMDV 31 0 3.16 5/5
32 0 2.99
33 0 3.16
34 0.03 3.05
35 0 N2.99
Gal-FMDV 36 0 2.86 5/5
37 0.03 3.15
38 0 2.86
39 0.01 N2.86
40 0 2.77
PBS 41 0.01 0 0/5
42 0 0
43 0 NDa
44 0 ND
45 0 ND
a Not done.
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achieved if the neutralizing titer in the suckling mouse
protection assay is above 2.0. As shown in Table 1, guinea
pigs inoculated with 100 Ag of IgG-FMDV fusion protein
displayed strong neutralizing activities against serotype O
FMDV at week 3 (neutralizing titer N 3.75). Although the
neutralizing level decreased somewhat at week 7, the
neutralizing titer still remained above 3. High neutralizing
activities were also observed when guinea pigs were
inoculated with Gal-FMDV fusion protein. The negative
control guinea pigs injected with either PBS or IgG heavy
chain constant region without FMDV epitopes did not
develop neutralizing activities.
IgG-FMDV induced T-cell proliferative responses and
high levels of neutralizing antibody response. We then test
whether IgG-FMDV can protect guinea pigs against
FMDV infection. For this purpose, all immunized guinea
pigs were challenged by direct inoculation with 100 ID50
serotype O FMDV. The animals were then observed daily
for clinical signs of FMD. All immunized guinea pigs
given IgG-FMDV or Gal-FMDV fusion protein were
completely protected and ate and behaved normally during
the observation period (Table 1). In contrast, in the
negative control group, all the guinea pigs presented
characteristic signs of FMD within 3 days post-challenge,
those included vesicles on the feet and tongue and high
body temperature.
Neutralizing antibody response and viral challenge assays
in swine immunized with two inoculations of the fusion
proteins
We next sought to determine whether the fusion protein
could elicit protective immune responses in swine, which
are economically important hosts known to be highly
susceptible to FMDV infection. The swine experiment
contained two groups of five swine that were each
inoculated twice at an interval of 3 weeks with 400 Ag of
purified IgG-FMDV or Gal-FMDV. The experiment also
included five swine that were inoculated with PBS.
Neutralizing antibody response and protection of the
animals against FMDV challenge were assayed 3 weeks
after the secondary inoculation. The results were summar-Table 1
Neutralizing antibody titers and viral challenge assays in guinea pigs
Groups No. of
guinea pigs
Neutralizing titersa No. protected/
No. challengedWeek 0 Week 3 Week 7
IgG-FMDV 6 0 N3.75 3.02 6/6
Gal-FMDV 6 0 N3.75 N3.25 6/6
IgGb 6 0.01 0 0 0/6
PBS 6 0 0 0 0/6
a A mouse protection test was performed to determine the induction of
neutralizing antibody responses in tested animals. Titer is the surplus
between the log of LD50 in experiment group and that in control group.
b Swine IgG heavy chain constant region without FMDV epitope.ized in Table 2. The neutralizing titers were above 2.5 in
both IgG-FMDV- and Gal-FMDV-immunized swine. There
was no significant difference in the antibody titer between
the two groups. The animals were challenged with serotype
O FMDV. All of the immunized animals showed no signs of
infection through the course of the experiment. Whereas the
animals given PBS developed severe FMD with vesicles
and high fever.
Neutralizing antibody response and viral challenge assays
in swine immunized with a single inoculation of the fusion
proteins
Two inoculations of IgG-FMDV protein in swine were
able to induce a high level of neutralizing antibody and
protect the animals against viral challenge. We then test the
efficiency of a single inoculation of IgG-FMDV protein in
swine. Two groups of 10 swine each were immunized with
a single inoculation of 800 Ag of purified IgG-FMDV or
Gal-FMDV protein. The neutralizing antibody levels in
sera were assayed at weeks 6 and 10 post-inoculation. As
shown in Table 3, the neutralizing antibody level reached
approximately 2.7 at week 6 and 2.0 at week 10 in the
IgG-FMDV-inoculated group. However, the neutralizing
antibody titers in sera from swine inoculated with Gal-
FMDV protein were lower than 1.0 at weeks 6 and 10
post-inoculation.
The swine were challenged with 100 ID50 swine
infectious dose FMDV at week 10 post-inoculation. All
five swine in the IgG-FMDV-inoculated group showed no
FMD clinical symptoms during the 14-day observation
period. But one animal receiving Gal-FMDV protein
exhibited vesicles on the feet at day 4 post-challenge,
and the other four swine also developed severe FMD
several days later. This result agrees with our previous
study, which showed a single inoculation of Gal-FMDV
Table 3
Neutralizing antibody response and viral challenge assays in swine
receiving a single inoculation
Groups Animal no. Neutralizing titers No. protected/
No. challengedWeek 0 Week 6 Week 10
IgG-FMDV 11 0 2.77 2.23 5/5
12 0.05 2.77 2.00
13 0 2.63 N2.00
14 0.01 ND ND
15 0 ND ND
Gal-FMDV 16 0 0.44 0.77 0/5
17 0 0.75 0.50
18 0 0.77 0.63
19 0.01 ND ND
20 0 ND ND
PBS 21 0 0 0 0/4
22 0.02 0 0
23 0 ND ND
24 0 ND ND
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guinea pigs.Discussion
It has been shown that fusion protein FMD vaccines
have a stronger immunogenicity and longer half-life
compared with short peptides corresponding to immuno-
genic epitopes (Bona et al., 1994; Syred et al., 1987).
Immunoglobulin (Ig) has been suggested as an ideal carrier
protein for microbial peptides because of its various
advantages such as high efficacy to deliver antigenic
peptide, safety, and long half life (Bona et al., 1994). The
chimeric protein where the CDR3 region of Ig is replaced
with immunogenic epitope was able to induce immune
responses efficiently (Zaghouani et al., 1993, 1995). In our
previous study, we tried to use swine IgG heavy chain as
the carrier for FMDV epitopes. A chimeric protein (L-IgG-
FMDV) was constructed by replacing the CDR3 loop of
swine IgG single heavy chain with the antigenic FMDV
peptide (aa141–160)–(aa21–40)–(aa141–160). But L-IgG-
FMDVonly induced weak T-cell responses and neutralizing
activities in guinea pigs and swine and failed to protect the
animals against FMDV challenge (Zhao et al., 2000). In the
current study, a group of three swine that were immunized
twice with this fusion protein was also included in the viral
challenge assay. At day 10 post-challenge, all of these
swine developed FMD symptoms (data not shown),
indicating that the protein can just delay the progress of
disease.
In this study, the entire variable region of swine IgG
was deleted and the FMDV peptide was fused to the
carboxy terminus of the IgG constant region to create the
chimeric protein IgG-FMDV. This fusion protein can elicit
a strong immune response in guinea pigs and swine and
fully protect the animals against FMDV infection. In
addition, we also constructed mammalian expressionplasmids encoding IgG-FMDV or L-IgG-FMDV. Intra-
muscular inoculation with the plasmid L-IgG-FMDV failed
to protect immunized animals against FMDV challenge
(unpublished data). But the IgG-FMDV encoding plasmid
was able to elicit recognizable cellular and humoral
immune responses in guinea pigs and 66% of the immu-
nized guinea pigs were protected from FMDV infection (Li
et al., 2001). These data suggested that swine heavy chain
constant region is more suitable to act as the carrier protein
for FMDV antigenic peptide (aa141–160)–(aa21–40)–
(aa141–160). We believe that the IgG-FMDV has a more
adaptable three-dimensional structure than L-IgG-FMDV
that exposes the immunogenic sites to the host immune
system.
Our previous study showed that a single inoculation of
Gal-FMDV only elicits weak immune responses in guinea
pigs and swine and cannot protect the immunized animals
against FMDV infection, even when up to 5 mg of the
fusion protein was used (unpublished data). However, when
testing the efficiency of a single inoculation of IgG-FMDV,
we found that swine developed protective immune
responses. We can offer no definitive explanation for the
difference between the immune responses induced by the
two fusion proteins. One possibility may be a difference in
the uptake of IgG-FMDV and Gal-FMDV by antigen
presenting cells. It has been previously shown that Igs are
taken up by various types of antigen presenting cells such as
dendritic, spleen, and B cells (Bona et al., 1994). In
functional assays of the influenza virus hemagglutinin
presentation, Ig-peptide was proved to be delivered to T-
cells more efficiently than free peptide or influenza virus
(Zaghouani et al., 1993). Another possible explanation is
that IgG-FMDV is more stable than Gal-FMDV in vivo,
resulting in a longer exposure of the immunogen to the
immune system. An alternative explanation is that the IgG
constant region has inherent immunopotentiating properties
when used as a carrier protein fused to the immunogen.
Further work is necessary to better understand the nature of
the protective immune response to FMDV induced by IgG-
FMDV.
Although VP1-based peptide vaccines often induce high
level of immunogenicity, they do not always achieve
protection against FMDV challenge in livestock. Part of
the low efficacy may originate in the hypervariability of the
immunogenic sites, expected from the quasi-species genetic
structure of FMDV (Grubman and Baxt, 2004). In a large-
scale bovine vaccination study using synthetic peptides,
Taboga et al. (1997) detected viral escape mutants that were
antigenic variants of the challenge virus in vaccinated,
unprotected animals. Thus, a possible increase in the
efficiency of peptide vaccines may be attained by enlarging
the repertoire of independent B cell and T-cell epitopes,
together with variant forms of some of them. Another
approach to overcome the antigenic variance problem is to
incorporate consensus residues into the hypervariable
positions of the VP1 sites and this approach has been
G. Li et al. / Virology 328 (2004) 274–281 279shown to provide for broad immunogenicity in swine.
Although IgG-FMDV exhibited potency and efficacy in the
homologous virus challenge assay, further studies are
required to test the efficiency of this vaccine candidate in
other species.Materials and methods
Viruses
The serotype O FMDV used to challenge guinea pigs and
swine was strain Hongkong/1999 passaged 2–4 times in
sucking mice.
Expression plasmid construction
Plasmid pBSK-IgG carrying the full length of swine IgG
heavy chain gene was as described previously (Zhao and
Zheng, 1999). PCR was used to amplify the swine single
heavy chain constant region from the plasmid pBSK-IgG
using a pair of swine IgG gene specific primers: swine IgG-
5V specific primer 5V ACGGGATCC (BamHI) TCAG-
CCCCCAAGACGC3V and swine IgG-3V specific primer
5VACCGGAATTC(EcoRI) TTTACCCTGAGTCTTGC3V.
Restriction sites used for subcloning are underlined in each
primer.
DNA fragments encoding peptides spanning residues
21–40 and 141–160 of FMDV VP1 protein were chemically
synthesized and were ligated into a sequence (aa141–160)–
(aa21–40)–(aa141–160). Restriction sites EcoRI and PstI
were added to the 5V and 3V ends, respectively. This
immunogenic sequence and the swine IgG single heavy
chain constant region gene were then cloned into the
pTricHis vector (Invitrogen, CA, USA) at the BamHI/PstI
sites. The construct thus created encodes a fusion protein
(IgG-FMDV) that consists of an immunogenic dominant
epitope linked to the carboxy terminus of swine heavy chain
constant region (Fig. 1). The DNA sequence was also fused
to carboxy terminus of the h-galactosidase gene by cloning
into the plasmid pWR590 at EcoRI/BamHI sites as
described previously (Huang et al., 1999). This fusion
protein was named Gal-FMDV.
Fusion protein expression, purification, and Western blot
assays
The IgG-FMDV fusion protein was produced in the E.
coli TOP10 strain. Cells were grown at 37 8C to an OD600
of 0.5–0.6, followed by induction with 1 mM of isopropyl-
h-d-thiogalactoside (IPTG) for 6 h. Cells were harvested by
centrifugation, resuspended and then disrupted by sonica-
tion. The lysate was centrifuged and inclusion body pellets
were dissolved in 8 M urea. The solubilized samples were
then purified by a His-tagged affinity column according to
manufacturer’s instructions (Clontech, CA, USA). The Gal-FMDV fusion protein was prepared as described previously
(Huang et al., 1999).
The presence of the FMDV insert was confirmed by
Western blot analysis. Briefly, a 10% polyacrylamide gel
was used for protein separation, and the protein was
transferred to a nitrocellulose membrane. The membrane
was then incubated with anti-Rabbit FMDVantibody at 4 8C
over night. After washing, the membrane was incubated
with anti-guinea pig IgG conjugated with horseradish
peroxidase for 1 h at room temperature. The membrane
was washed and then incubated with O-phenylenediamine
(OPD) containing 0.05% H2O2 (30% W/V) until bands were
of the proper intensity.
Vaccine preparation
To prepare oil adjuvant vaccine, the aqueous protein was
emulsified with Montanide ISA206 (Seppic, France) to form
a water-in-oil-in-water blend. The ratio of aqueous protein
to the oil adjuvant was 50:50.
Animals and vaccination
Male and female Dunkan–Hartley guinea pigs weighing
250–300 g and large white swine, 2- to 3-month-old and
approximately 40–50 kg, were used in this study. All of the
animals were housed at disease secure isolation facilities in
an FMDV-free area and were free of previous FMD contact
as confirmed by the absence of detectable anti-FMDV
antibodies in the serum (Fig. 2A and Tables 1–3). Each
guinea pig in a group of six guinea pigs was vaccinated by
intramuscular inoculation with 0.2 ml of vaccine containing
50 Ag of purified fusion protein. After 3 weeks, the guinea
pigs were boosted with the same dose of purified fusion
protein. The control groups were inoculated with phosphate-
buffered saline (PBS) or the swine heavy chain constant
region without FMDV epitopes.
Swine experiment 1: swine immunized with two
inoculations of fusion proteins. Fifteen swine were
separated into three groups. Two groups of ten swine
each was injected intramuscularly in the neck area with
400 Ag of purified IgG-FMDV or Gal-FMDV fusion
protein. The animals were boosted 3 weeks later with
400 Ag of the fusion protein. The negative control group
consisted of five unvaccinated swine. Blood samples were
obtained for neutralizing antibody level assays at week 3
post-secondary inoculation, and then viral challenge assays
were performed.
Swine experiment 2: swine immunized with a single
inoculation of fusion proteins. Fourteen swine were
separated into three groups. One group of five animals each
was inoculated with 800 Ag of purified IgG-FMDV protein.
The other group of five animals each was inoculated with
800 Ag of purified Gal-FMDV protein. The control group
contained four animals, which were inoculated with PBS.
The neutralizing antibody levels were assayed at weeks 6
G. Li et al. / Virology 328 (2004) 274–281280and 10 post-inoculation, respectively, and then viral
challenge assays were performed.
T-cell proliferation assay in guinea pigs
T-cells were isolated by 1.077 g/ml Percoll solution
(Pharmacia) from spleen of guinea pigs 3 weeks after the
secondary inoculation and were cultured in triplicate using
96-well flat-bottom plates at a concentration of 1  106 cell/
ml. The cells were stimulated with five 2-fold serial
dilutions of pure type O FMDV antigen at 37 8C for 4
days. During the last 12 h of culture, each well was pulsed
with 0.5 ACi of [3H]thymidine. The cells were harvested and
the uptake of [3H]thymidine was detected using a liquid
scintillation counter (Beckmon LS6500). Results were
obtained as mean counts per minute (cpm) and expressed
as stimulation index (SI; mean cpm of cultures with antigen
divided by mean cpm of cultures without antigen). The
response was considered significant only when the SI was
2.0 or higher.
Neutralizing antibody assays
To determine the induction of neutralizing antibody
responses in guinea pigs and swine, a mouse protection test
was performed according to the procedures described
elsewhere (Huang et al., 1999; Mulcahy et al., 1991).
Briefly, suckling mice (6 groups of 10 each) were injected
by neck-subcutaneous route with 100 Al of the serum
obtained from the fusion protein-immunized animals and
control groups. After 24 h, suckling mice were challenged
with 100 Al of 10-fold serially diluted virus (i.e., 103, 104,
105, 106, 107, and 108) (serotype O FMDV). The virus
dilution required to kill 50% of suckling mice was defined
as one half of lethal dose (LD50) and estimated by the Reed–
Muench method (Reed and Muench, 1938). Neutralizing
antibody titer was expressed as the surplus between the log
of LD50 in the experiment group and that in the control
group.
Viral challenge assays in guinea pigs and swine
FMDV challenge assays in immunized animals were
performed as described previously (Huang et al., 1999).
Briefly, 3 weeks after secondary immunization, each guinea
pig was inoculated intradermally in each of the rear feet with
0.2 ml of viral solution containing 100 guinea pig infectious
dose (100 ID50) serotype O FMDV. Challenge tests in swine
were carried out by intramuscular injection of each animal
with 2 ml of swine infectious dose (100 ID50) in the neck
region. After challenge assay, all of the animals were
examined daily for clinical signs of FMD such as increase in
body temperature (above 41 8C) and the appearance of
vesicles on the mouth or hooves. Observation was
terminated on day 14 post-challenge and the animals were
humanely euthanized.Acknowledgments
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